Adamax (Dihexa) Research: HGF/c-Met Potentiation and Cognitive Biology

Adamax (Dihexa, PNB-0408) is a synthetic peptidomimetic derived from the angiotensin IV analogue Norleucine1-angiotensin IV (Nle1-AngIV) through systematic structural optimisation for blood-brain barrier penetration, oral bioavailability, and metabolic stability. Developed by Joseph Harding and colleagues at Washington State University, Dihexa targets the HGF (hepatocyte growth factor)/c-Met receptor tyrosine kinase signalling axis as a potentiator of neuroplasticity and synaptogenesis.

Pharmacological Mechanism

HGF/c-Met Potentiation: The primary pharmacological mechanism of Dihexa is potentiation of HGF-mediated c-Met receptor tyrosine kinase activation. HGF is a pleiotropic growth factor acting through c-Met (MET, hepatocyte growth factor receptor) — a receptor tyrosine kinase expressed in neurons, hepatocytes, epithelial cells, and many other cell types. c-Met activation drives: synaptogenesis (dendritic spine formation), axonal guidance, neuronal survival (PI3K/Akt anti-apoptotic signalling), and hepatocyte proliferation/migration.

McCoy et al. (Journal of Pharmacology and Experimental Therapeutics, 2010) published that Dihexa and related angiotensin IV analogues potentiate HGF-stimulated c-Met signalling at picomolar concentrations — an extraordinary potency suggesting high-affinity binding to a site that allosterically enhances HGF/c-Met interaction. The published potency (approximately 10^7-fold greater than HGF itself in some assay formats) has generated both interest and methodological scrutiny, making careful experimental design essential for rigorous Dihexa research.

IRAP/AT4 Receptor: The original AT4 receptor hypothesis proposes that Dihexa and angiotensin IV analogues inhibit IRAP (insulin-regulated aminopeptidase, also known as leucine-cystinyl aminopeptidase LNPEP), protecting endogenous neuropeptides from degradation. IRAP is a zinc-dependent aminopeptidase localised in GLUT4 storage vesicles in neurons. Its inhibition would extend the half-life of oxytocin, vasopressin, and other IRAP substrates, potentially contributing to cognitive enhancement through neuropeptide system amplification. Whether IRAP inhibition or HGF/c-Met potentiation is the primary mechanism remains an active research question that can be directly addressed using selective pharmacological tools.

Research Design Considerations

Concentration-response characterisation: Given the extraordinary potency claims, rigorous concentration-response research is essential. Prepare Dihexa in DMSO at 10mM stock, then perform 10-fold serial dilutions in culture medium across a range from 1fM to 10µM (10 log units). Use low-binding plasticware (polypropylene tubes and plates) to minimise adsorption at sub-nanomolar concentrations. Include vehicle controls at matched DMSO concentration (less than 0.1% final) at every concentration point.

Pathway confirmation controls: c-Met-selective inhibitor crizotinib (100nM) or c-Met-selective antibody (MetMAb, 10µg/mL) as pre-treatment before Dihexa plus sub-threshold HGF should abolish potentiation if the mechanism is c-Met-dependent. IRAP inhibitor HFI-419 (1µM) in parallel experiments can be used to dissect the IRAP contribution.

HGF-potentiation assay design: Use HGF at its EC20 concentration (producing 20% of maximal c-Met phosphorylation, sub-saturating) to create a window for potentiation detection. Add Dihexa (1fM-10nM) to HGF-EC20 and measure: c-Met phosphorylation at pTyr1234/1235 (activation loop, Western blot or PathScan ELISA); downstream Akt phosphorylation (Ser473); ERK1/2 phosphorylation (Thr202/Tyr204); and cell scatter (if using MDCK cells, a classical c-Met activation endpoint).

Synaptogenesis Research

The neuroplasticity dimension of Dihexa research uses primary rat hippocampal neurons (embryonic day 18, culture to DIV7) plated at low density (30,000 cells/cm2) on poly-D-lysine/laminin-coated coverslips. Treat with Dihexa (1pM-10nM) in Neurobasal-B27 for 72 hours beginning at DIV7 (the active synaptogenesis period). Fix and stain for: synapsin-1 (pre-synaptic marker), PSD-95 (post-synaptic density marker), MAP2 (dendritic marker), and drebrin (dendritic spine marker). Automated image analysis of synaptic puncta density (synapsin-1 puncta per µm of MAP2-positive dendrite) quantifies synaptogenic activity.

Key Published Research

• McCoy AT, et al. "Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents." Journal of Pharmacology and Experimental Therapeutics, 2010. PMID: 20826566
• Wright JW, Harding JW. "The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease." Journal of Alzheimer's Disease, 2015. PMID: 25471195
• Benoist CC, et al. "Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV." Journal of Pharmacology and Experimental Therapeutics, 2011. PMID: 21183612

View Adamax (Dihexa) →

For laboratory and analytical research purposes only. Not for human or veterinary use.

Dihexa in Memory Research Models

The cognitive biology dimension of Dihexa research uses established spatial memory and pattern separation paradigms in rodent models. The Morris water maze tests hippocampal-dependent spatial reference memory: rodents learn the location of a hidden platform in a circular pool using extramaze visual cues. Dihexa-treated aged rats or those with hippocampal impairment (scopolamine-induced, or in transgenic Alzheimer models) are assessed for platform location learning rate (acquisition phase) and memory retention (probe trial, platform removed). Shorter latency to platform and higher probe trial time in target quadrant indicate improved spatial memory.

Object pattern separation in the touchscreen-based pairwise discrimination task tests dentate gyrus-dependent cognitive function — the hippocampal subregion most sensitive to age-related neurogenesis decline and c-Met expression changes. This task requires animals to discriminate between pairs of visual objects, with difficulty increasing as stimuli become more similar (pattern separation challenge). Dihexa effects on pattern separation performance characterise dentate gyrus-specific cognitive effects beyond simple spatial learning.

Dihexa and Neurogenesis

Adult hippocampal neurogenesis in the subgranular zone of the dentate gyrus is regulated by HGF/c-Met signalling — c-Met is expressed on adult hippocampal neural progenitor cells (NPCs), and HGF promotes NPC proliferation and survival. Dihexa's HGF potentiation mechanism therefore predicts potential neurogenesis-stimulating effects.

For neurogenesis research: BrdU (50mg/kg, daily for 5 days) or EdU labelling of proliferating cells in vivo during Dihexa treatment. At day 14 (neuroblast stage) and day 28 (mature neuron stage) after BrdU injection, perfuse and section hippocampus. Co-stain with BrdU and neuronal markers (NeuN for mature neurons, DCX for neuroblasts) and quantify BrdU+/NeuN+ cells in the granule cell layer. In vitro: adult rat hippocampal NPCs isolated by neurosphere formation assay. Treat with Dihexa (1pM-10nM) during proliferation phase (EGF + FGF2 medium) then during differentiation phase (growth factor withdrawal). Measure: neurosphere number and diameter (proliferation); and neuron, astrocyte, oligodendrocyte ratios in differentiated cultures (fate specification).

Dihexa Blood-Brain Barrier Penetration Research

A central design objective in Dihexa's development was blood-brain barrier (BBB) penetration — the ability to reach central nervous system targets following systemic administration. McCoy et al. developed Dihexa specifically to overcome the BBB limitations of the parent hexapeptide Nle1-angiotensin IV. The N-hexanoyl modification and C-terminal amide increase lipophilicity (calculated logP approximately 2.1 for Dihexa versus negative values for the parent hexapeptide), improving passive transcellular diffusion across the BBB.

For BBB penetration research: the PAMPA-BBB assay (parallel artificial membrane permeability assay using phosphatidylcholine membranes as a BBB model) provides a rapid, high-throughput estimate of passive BBB permeability. Prepare Dihexa in PBS pH 7.4 at 100µM. Apply to donor compartment of PAMPA plate. After 4 hours at 25°C, measure concentration in acceptor compartment by UV absorbance (Dihexa has aromatic absorption from the Tyr residue) or LC-MS/MS. Calculate permeability coefficient Pe (cm/s). Values above 10 × 10^-6 cm/s indicate high passive BBB permeability by this model.

For CNS target engagement confirmation: measure c-Met phosphorylation in hippocampal tissue homogenates from Dihexa-treated rodents by Western blot (pMet/total Met ratio). CNS c-Met phosphorylation after systemic Dihexa administration confirms that sufficient compound reaches the brain to engage the target — a critical pharmacodynamic biomarker linking plasma exposure to central pharmacological action.

Dihexa and Hippocampal Long-Term Potentiation Research

Long-term potentiation (LTP) in hippocampal area CA1 is the canonical cellular model of memory formation — synaptic strengthening produced by high-frequency stimulation that persists for hours to weeks and shares molecular mechanisms with spatial memory acquisition. HGF/c-Met signalling has been directly implicated in LTP induction and maintenance: c-Met activation promotes AMPA receptor trafficking to the synapse (synaptic insertion of GluA1-containing AMPA receptors), increases dendritic spine density, and facilitates the structural plasticity underlying late-phase LTP.

For hippocampal slice LTP research with Dihexa: prepare acute transverse hippocampal slices (400µm, adult male rats, maintained in ACSF at 32°C). Allow 1-hour recovery after slicing. Place stimulating electrode in Schaffer collateral pathway (CA3 axons projecting to CA1 stratum radiatum). Place recording electrode in CA1 stratum radiatum to measure field excitatory postsynaptic potentials (fEPSPs). Establish stable baseline (20 minutes, 0.05Hz stimulation). Apply Dihexa (1pM-10nM) in ACSF bath for 20 minutes before and during theta-burst stimulation (TBS: 4 pulses at 100Hz, repeated 10 times at 5Hz, for 4 trains). Record fEPSP slope for 60 minutes after TBS to quantify LTP magnitude (percentage of baseline). Include c-Met inhibitor crizotinib (100nM, 30-minute pre-treatment) as a mechanistic control — if crizotinib prevents Dihexa-enhanced LTP, this confirms c-Met dependence.

Dihexa Comparison with Other Cognitive Enhancers

Contextualising Dihexa within the broader cognitive enhancement research landscape requires comparison with established positive controls. Three mechanistically distinct comparison compounds provide complementary reference points.

Donepezil (acetylcholinesterase inhibitor, clinically approved for Alzheimer disease) enhances cholinergic neurotransmission — a different mechanism from HGF/c-Met potentiation. Comparing donepezil and Dihexa in Morris water maze performance in the same aged rodent cohort characterises whether HGF/c-Met potentiation provides cognitive effects additive to cholinergic enhancement.

BDNF (at 1µg/mL in hippocampal slice preparations) directly activates TrkB, producing LTP facilitation through MAPK/ERK-dependent synaptic protein synthesis. Comparing BDNF-enhanced LTP with Dihexa-enhanced LTP using matched recording protocols characterises the relative contribution of HGF/c-Met versus BDNF/TrkB pathways to hippocampal synaptic plasticity.

IGF-1 LR3 (HGF shares receptor superfamily proximity with IGF-1 in class IV plexin-semaphorin-integrin superfamily context) can be used in parallel to distinguish RTK-class effects from HGF/c-Met-specific effects in the same neural preparation.